CERS

(redirected from Cerus Corporation)
AcronymDefinition
CERSCerus Corporation (stock symbol)
CERSCenter for Excellence in Rural Safety (University of Minnesota)
CERSConsumer Education and Research Society (Ahmedabad, India)
CERSCentre for Relationship Marketing and Service Management (Hanken School of Economics; Helsinki, Finland)
CERSCertified Expert Recovery Specialist (Lunarline School of Cybersecurity; various locations)
CERSCertified Employee Retention Specialist
CERSCommittee to Elect a Republican Senate (Wisconsin)
CERSCrew Emergency Rescue System
CERSCrew Equipment Retrieval System
CERSCollection/Exam Referral System
CERSCarrier Evaluation & Reporting System
CERSCommander Emergency Recovery Section
CERSClass Event and Resource Scheduler (STASS)
CERSCombat Environment Realism System
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Moreover, in December 2018, Cerus Corporation announced the initiation and first patient enrollment in a Phase III study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures.
Ltd, Haemonetics Corporation, Fresenius Kabi AG, Kawasumi Laboratories Inc., Cerus Corporation, NIKKISO CO., LTD., Medica S.p.A., Therakos, Inc.
Biomedical products company Cerus Corporation (Nasdaq:CERS) announced on Monday its unaudited preliminary product revenue of USD16.5m for the fourth quarter 2018
Cerus Corporation announced that the American Red Cross has received approval by the U.S.
Biomedical company Cerus Corporation (Nasdaq:CERS) reported on Tuesday that it has entered into a purchase agreement for the INTERCEPT Blood System for platelets and plasma with The Community Blood Center (CBC).
The first patient has been dosed in Cerus Corporation's (NASDAQ:CERS) Phase I clinical trial of CRS-100, the company's lead immunotherapy product.
(Nasdaq: MEDI) and Cerus Corporation (Nasdaq: CERS) have signed an agreement for developing and commercializing a novel therapeutic vaccine designed to treat cancers of the breast, prostate and colon, as well as metastatic melanomas.
Cerus Corporation, Concord, CA, announced it has initiated a Phase IB clinical trial for its allogeneic cellular immune therapy (ACIT) in collaboration with the National Marrow Donor Program, Minneapolis, MN.
Cerus Corporation (Nasdaq:CERS), Concord, Calif., has announced results for the third quarter ended September 30, 2001.
Cerus Corporation (Nasdaq:CERS) and Baxter Healthcare Corporation have submitted a CE Mark application for approval to market the Intercept Platelet System in Europe.
Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, and Medica S.p.A.